Phase 2 Depression and Anxiety Trial, Recruiting NCT07610473 Sponsor: Draig Therapeutics Ltd Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT07610473
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to read, understand, and communicate in the local language used at the trial site, and are willing to sign a consent form
  • You are between 18 and 75 years old (inclusive) at the time of signing the consent form
  • You have been diagnosed with recurring depression (meaning you have had at least one episode of depression in the past, separate from your current one), based on standard medical diagnostic guidelines (DSM-5-TR)

Who may not be able to join:

  • You are currently pregnant, breastfeeding, or planning to become pregnant during the study
  • You have a medical condition or ongoing chronic illness that is not currently stable or well-managed
  • You have a significant neurological condition affecting the brain or nervous system (confirm with trial site)
  • You have had a moderate or severe problem with alcohol or drug use in the 6 months before your screening appointment, as defined by standard diagnostic guidelines
  • You have a history of seizures
  • In the opinion of the trial doctor, you may have difficulty following the trial's requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +44(0)2920028450

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Draig Therapeutics Ltd
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 56

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov